Vital Therapies

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch VTL and buy or sell other stocks, ETFs, and their options commission-free!

About VTL

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. 

CEO
Daniel Vitt, PhD
CEODaniel Vitt, PhD
Employees
Employees
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2003
Founded2003
Employees
Employees

VTL Key Statistics

Market cap
150.03M
Market cap150.03M
Price-Earnings ratio
-1.54
Price-Earnings ratio-1.54
Dividend yield
Dividend yield
Average volume
2.02M
Average volume2.02M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$1.51
52 Week high$1.51
52 Week low
$0.5062
52 Week low$0.5062

Stock Snapshot

The current Vital Therapies(VTL) stock price is $7.76, with a market capitalization of 150.03M. The stock trades at a price-to-earnings (P/E) ratio of -1.54.

On 2026-04-02, Vital Therapies(VTL) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for Vital Therapies(VTL) stock has reached 0, versus its average volume of 2.02M.

The stock's 52-week range extends from a low of $0.51 to a high of $1.51.

The stock's 52-week range extends from a low of $0.51 to a high of $1.51.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.